Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.
Identifieur interne : 000C36 ( PubMed/Corpus ); précédent : 000C35; suivant : 000C37Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.
Auteurs : Sarah Vautier ; Aline Milane ; Christine Fernandez ; Helene Chacun ; Lucette Lacomblez ; Robert FarinottiSource :
- Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques [ 1482-1826 ] ; 2009.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, ATP Binding Cassette Transporter, Sub-Family G, Member 2, ATP-Binding Cassette Transporters (genetics), ATP-Binding Cassette Transporters (metabolism), Animals, Antiparkinson Agents (pharmacokinetics), Biological Transport, Blood-Brain Barrier (metabolism), Blotting, Western, Brain (metabolism), Bromocriptine (pharmacokinetics), Disease Models, Animal, Gene Expression Regulation, Injections, Intraperitoneal, MPTP Poisoning (physiopathology), Male, Mice, Mice, Inbred C57BL, P-Glycoprotein, P-Glycoproteins, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Tissue Distribution.
- MESH :
- chemical , pharmacokinetics : Antiparkinson Agents, Bromocriptine.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, ATP Binding Cassette Transporter, Sub-Family G, Member 2, P-Glycoprotein, P-Glycoproteins.
- drug therapy : Parkinson Disease.
- genetics : ATP-Binding Cassette Transporters.
- metabolism : ATP-Binding Cassette Transporters, Blood-Brain Barrier, Brain.
- physiopathology : MPTP Poisoning, Parkinson Disease.
- Animals, Biological Transport, Blotting, Western, Disease Models, Animal, Gene Expression Regulation, Injections, Intraperitoneal, Male, Mice, Mice, Inbred C57BL, Tissue Distribution.
Abstract
MPTP-induced dopaminergic degeneration is an experimental model commonly used to explore Parkinson's disease. Cerebral drug transport by ABC transporters in MPTP models has never been reported.
PubMed: 19732497
Links to Exploration step
pubmed:19732497Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.</title><author><name sortKey="Vautier, Sarah" sort="Vautier, Sarah" uniqKey="Vautier S" first="Sarah" last="Vautier">Sarah Vautier</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy EA 2706, University Paris Sud XI, Chatenay-Malabry, France. sarahvautier@hotmail.com</nlm:affiliation></affiliation></author><author><name sortKey="Milane, Aline" sort="Milane, Aline" uniqKey="Milane A" first="Aline" last="Milane">Aline Milane</name></author><author><name sortKey="Fernandez, Christine" sort="Fernandez, Christine" uniqKey="Fernandez C" first="Christine" last="Fernandez">Christine Fernandez</name></author><author><name sortKey="Chacun, Helene" sort="Chacun, Helene" uniqKey="Chacun H" first="Helene" last="Chacun">Helene Chacun</name></author><author><name sortKey="Lacomblez, Lucette" sort="Lacomblez, Lucette" uniqKey="Lacomblez L" first="Lucette" last="Lacomblez">Lucette Lacomblez</name></author><author><name sortKey="Farinotti, Robert" sort="Farinotti, Robert" uniqKey="Farinotti R" first="Robert" last="Farinotti">Robert Farinotti</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19732497</idno><idno type="pmid">19732497</idno><idno type="wicri:Area/PubMed/Corpus">000C36</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C36</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.</title><author><name sortKey="Vautier, Sarah" sort="Vautier, Sarah" uniqKey="Vautier S" first="Sarah" last="Vautier">Sarah Vautier</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy EA 2706, University Paris Sud XI, Chatenay-Malabry, France. sarahvautier@hotmail.com</nlm:affiliation></affiliation></author><author><name sortKey="Milane, Aline" sort="Milane, Aline" uniqKey="Milane A" first="Aline" last="Milane">Aline Milane</name></author><author><name sortKey="Fernandez, Christine" sort="Fernandez, Christine" uniqKey="Fernandez C" first="Christine" last="Fernandez">Christine Fernandez</name></author><author><name sortKey="Chacun, Helene" sort="Chacun, Helene" uniqKey="Chacun H" first="Helene" last="Chacun">Helene Chacun</name></author><author><name sortKey="Lacomblez, Lucette" sort="Lacomblez, Lucette" uniqKey="Lacomblez L" first="Lucette" last="Lacomblez">Lucette Lacomblez</name></author><author><name sortKey="Farinotti, Robert" sort="Farinotti, Robert" uniqKey="Farinotti R" first="Robert" last="Farinotti">Robert Farinotti</name></author></analytic><series><title level="j">Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</title><idno type="eISSN">1482-1826</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>ATP Binding Cassette Transporter, Sub-Family G, Member 2</term><term>ATP-Binding Cassette Transporters (genetics)</term><term>ATP-Binding Cassette Transporters (metabolism)</term><term>Animals</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Biological Transport</term><term>Blood-Brain Barrier (metabolism)</term><term>Blotting, Western</term><term>Brain (metabolism)</term><term>Bromocriptine (pharmacokinetics)</term><term>Disease Models, Animal</term><term>Gene Expression Regulation</term><term>Injections, Intraperitoneal</term><term>MPTP Poisoning (physiopathology)</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>P-Glycoprotein</term><term>P-Glycoproteins</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Tissue Distribution</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Bromocriptine</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>ATP Binding Cassette Transporter, Sub-Family G, Member 2</term><term>P-Glycoprotein</term><term>P-Glycoproteins</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>ATP-Binding Cassette Transporters</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>ATP-Binding Cassette Transporters</term><term>Blood-Brain Barrier</term><term>Brain</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>MPTP Poisoning</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Biological Transport</term><term>Blotting, Western</term><term>Disease Models, Animal</term><term>Gene Expression Regulation</term><term>Injections, Intraperitoneal</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Tissue Distribution</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">MPTP-induced dopaminergic degeneration is an experimental model commonly used to explore Parkinson's disease. Cerebral drug transport by ABC transporters in MPTP models has never been reported.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19732497</PMID><DateCreated><Year>2009</Year><Month>09</Month><Day>07</Day></DateCreated><DateCompleted><Year>2009</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1482-1826</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</Title><ISOAbbreviation>J Pharm Pharm Sci</ISOAbbreviation></Journal><ArticleTitle>Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.</ArticleTitle><Pagination><MedlinePgn>199-208</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">MPTP-induced dopaminergic degeneration is an experimental model commonly used to explore Parkinson's disease. Cerebral drug transport by ABC transporters in MPTP models has never been reported.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We have investigated the transport of bromocriptine through the blood-brain barrier (BBB) in a MPTP model to understand the influence of the dopaminergic degeneration on ABCB1 and ABCG2.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We have shown that in MPTP treated mice, bromocriptine is widely distributed to brain (2.3-fold versus control, p less than 0.001) suggesting either disruption of BBB or alteration of active efflux of the drug. In situ brain perfusion of [14C]- sucrose and [3H]-inulin did not evidenced a BBB disruption. Studies of ABCB1 and ABCG2 activity showed that MPTP intoxication did not alter their functionality. Conversely, ABCG2 expression studied on brain capillaries from MPTP-treated mice was decreased (1.3-fold, p less than 0.05) and ABCB1 expression increased (1.43-fold, p less than 0.05) as an off-setting of brain transport.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data demonstrate that MPTP intoxication does not alter the BBB permeability. However, bromocriptine brain distribution is increased in MPTP animals. Hence, MPTP may interact with another transport mechanism such as uptake and/or other efflux transporters. Inflammation and Parkinson's-like lesions induced by MPTP intoxication could lead to modification of drug pharmacokinetics and have clinical consequences, such as neurotoxicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vautier</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy EA 2706, University Paris Sud XI, Chatenay-Malabry, France. sarahvautier@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milane</LastName><ForeName>Aline</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Chacun</LastName><ForeName>Helene</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lacomblez</LastName><ForeName>Lucette</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Farinotti</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Pharm Pharm Sci</MedlineTA><NlmUniqueID>9807281</NlmUniqueID><ISSNLinking>1482-1826</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000070997">ATP Binding Cassette Transporter, Sub-Family G, Member 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501412">Abcg2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020168">P-Glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018435">P-Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>3A64E3G5ZO</RegistryNumber><NameOfSubstance UI="D001971">Bromocriptine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9P21XSP91P</RegistryNumber><NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.3.44</RegistryNumber><NameOfSubstance UI="C507084">Abcb1b protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015632" MajorTopicYN="N">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070997" MajorTopicYN="N">ATP Binding Cassette Transporter, Sub-Family G, Member 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001971" MajorTopicYN="N">Bromocriptine</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007274" MajorTopicYN="N">Injections, Intraperitoneal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020267" MajorTopicYN="N">MPTP Poisoning</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020168" MajorTopicYN="N">P-Glycoprotein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018435" MajorTopicYN="N">P-Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19732497</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000C36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:19732497
|texte= Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19732497" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |